Josh Neiman joined BeiGene in July 2018 and currently serves as Chief Commercial Officer, North America and Europe. Mr. Neiman is responsible for building and leading the commercial team and operations that will bring BeiGene’s innovative medicines to patients.
Mr. Neiman has broad U.S. and global oncology experience that spans marketing, sales, market access, lifecycle management, data and analytics. Most recently, Mr. Neiman was Vice President, Marketing at Flatiron Health from 2014 through its acquisition by Roche in 2018. Previously, Mr. Neiman served in a progression of commercial leadership roles at Onyx Pharmaceuticals and Genentech, Inc. where he was responsible for multiple aspects of commercialization for Kyprolis® (carfilzomib), Rituxan® (rituximab), Gazyva® (obinutuzumab), and Herceptin® (trastuzumab). Early in his career, Mr. Neiman worked as a research associate in drug discovery at Tao Biosciences and Plexxikon.

Mr. Neiman received his MBA from the Kellogg School of Management at Northwestern University and his B.A. from the University of California, Berkeley, in Molecular and Cell Biology.